Phase 1 Trial of Denosumab for Prevention of Bone Complications After Allogenic Hematopoietic Stem Cell Transplantation in Children
This clinical trial aimed to evaluate the safety and efficacy of Denosumab in preventing bone complications in pediatric patients following allogenic hematopoietic stem cell transplantation. The study was conducted by St. Justine's Hospital and was designed to assess the maximum tolerable dose and biological activity of Denosumab, a drug that inhibits bone resorption.
Indication: Disorder Related to Bone Marrow Transplantation
Modality: monoclonal antibody
Target: Bone complications after bone marrow transplantation in children
Sponsor: St. Justine's Hospital
Source URL: ClinicalTrials.gov
Source updated: Sep 06, 2018
Ingested: May 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Bone complications after bone marrow transplantation in children
View original source fields
Condition raw: Disorder Related to Bone Marrow Transplantation
Condition normalized: Disorder Related to Bone Marrow Transplantation
Modality raw: Disorder Related to Bone Marrow Transplantation
Modality normalized: monoclonal antibody
Target raw: Bone complications after bone marrow transplantation in children
Target normalized: Bone complications after bone marrow transplantation in children